CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SIGILON THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.Exclusive Patent License Agreement • March 18th, 2021 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
This Fourth Amendment ("Fourth Amendment)", effective as of December 10, 2020 (the "Fourth Amendment Effective Date"), is made by and between the Massachusetts Institute of Technology, a nonprofit research institution having a principal address at 77 Massachusetts Avenue, Cambridge, MA 02139 ("MIT") and Sigilon Therapeutics, Inc. (fka Sigilon, Inc.) a Delaware corporation, having a principal address at 100 Binney Street, Cambridge, MA 02142 ("Company") (each individually a "Party" and collectively the "Parties"), and amends that certain Exclusive Patent License Agreement between the Parties dated as of February 8, 2016, as previously amended by the First Amendment dated February 2, 2017, the Second Amendment dated August 9, 2018, and the Third Amendment dated November 6, 2019 (collectively, the "License Agreement"). Capitalized terms used herein without definition shall have the meaning given such terms in the License Agreement.
SECOND AMENDMENT TO LEASELease Agreement • March 18th, 2021 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is entered into as of January 19, 2021, by and between ARE-MA REGION NO. 45, LLC, a Delaware limited liability company (“Landlord”), and SIGILON THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
